Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/1/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Brian F. Issell MD

Wrong Dr. Brian F. Issell MD?

Associate Director

Phone: (808) ***-****  HQ Phone
University of Hawaii Cancer Center
677 Ala Moana Boulevard Suite 901
Honolulu, Hawaii 96813
United States

Company Description: The University of Hawai'i Cancer Center is the only National Cancer Institute-designated center in Hawai'i and the Pacific. The Center's mission is to reduce the...   more
Background

Employment History

Education

  • M.D.
  • MD
  • M.D
114 Total References
Web References
Brian F. Issell, MD
www.uhcancercenter.org, 3 Oct 2013 [cached]
Brian F. Issell, MD
...
Brian F. Issell, MD \n This e-mail address is being protected from spambots. You need JavaScript enabled to view it. " _mce_href="mailto: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it. | (808) 356-5794 Brian F. Issell, MD Associate Director
...
Dr. Issell's career has been committed to clinical and translational research to improve the care of cancer patients. In 2011, he continues this commitment at the University of Hawaii Cancer Center as Associate Director of Clinical Sciences and Translational Research. He has been a clinical and translational investigator, educator, administrator and practicing medical oncologist for over 30 years. From 1978-1983, he led the preclinical to clinical transition of several notable anticancer drugs in the US including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb). From 1983-1988, he led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novatis). From 1988-1999, he was Director of the University of Hawaii Cancer Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. From 1999 to 2006, he was Director of the Center's Clinical Sciences/Clinical Trials. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. He was Program Director of a K12 award for training clinical investigators and participated in T32 and R25 training awards held by the Cancer Center. From December 2006-December 2010, he was Vice President of Clinical Research/Medical Director of Academic Affairs for Scripps Health and Director of Clinical Research, Scripps Translational Science Institute which was awarded an NIH CTSA under his leadership of the clinical and regulatory components. He led the expansion of clinical research throughout Scripps Health multi-hospital system and took it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators. He returns to the University of Hawaii Cancer Center to help lead its transformation to a new level of investigator-initiated clinical and translational research of discoveries generated from Center research programs.
Publications Lillie, E.; Patay, B.; Diamant, J.; Issell, B.; Topol, E. The n-of -1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine 8: (2) 161-173, 2011. Maskarinec, G.; Pagano, I.; Lurie, G; Bantum, E.; Gotay,C.C.; Issell, B.F.; Factors Affecting Survival among Women with Breast Cancer in Hawaii. Journal of Women's Health, 20: (2) 231-237, 2011.
...
Issell, B.F.; Gotay, C.C.; Pagano, I; Franke, A.A.; Using Quality of Life Measures in a Phase I Clinical Trial of Noni in Patients with Advanced Cancer to Select a Phase II Dose. Journal of Dietary Supplements, 6: (4) 347-359, 2009. Issell, B.F.; Franke, A.; Fielding, R.M.: Pharmacokinetic Study of Noni Fruit Extract. Journal of Dietary Supplements, 5: (4) 373-382, 2008.
Leadership
www.uhcancercenter.org, 3 Oct 2013 [cached]
Brian Issell, MD Associate Director for Clinical Sciences and Translational Research
...
Brian Issell, MD Clinical and Translational Research Program
About Us | Scripps Translational Science Institute
www.stsiweb.org, 17 Aug 2010 [cached]
Brian Issell, MD
STSI Director of Clinical Research; SH, Medical Director of Academic Affairs
...
Brian Issell, MD, Vice-President of Scripps Health for Clinical Research, is the STSI Director of Clinical Research. He is exceptionally well qualified for his role on this CTSA proposal. A clinical and translational investigator, administrator and practicing medical oncologist for over 29 years, he led the preclinical to clinical transition of several notable anticancer drugs in the U.S. including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb) from 1978-1983, and he then led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novartis) from 1983-1988. In 1988 Dr. Issell was recruited to be director of the University of Hawaii's Cancer Research Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. Especially relevant to this application is Dr. Issell's previous role as Program Director of a K12 award for training clinical investigators and his participation in T32 and R25 training awards held by the Cancer Center. In December 2006, Dr. Issell was appointed Corporate Vice President of Clinical Research at Scripps Health. His charge in this role is to lead the expansion of clinical research throughout Scripps Health multi-hospital system and to take it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators.
Hospital Management RSS News
www.medworm.com [cached]
Dr. Brian Issell, head of the University of Hawaii's Clinical and Translational Research program, said that he has always encouraged patients to use the Internet as an educational arm… (Source: bizjournals.com Health Care:Hospitals headlines)
innomarkinc.com
www.innomarkinc.com, 17 Oct 2004 [cached]
Dr. Brian Issell, internist, oncologist and clinical sciences program director at the University of Hawaii cancer center, is principal investigator of the study, which began in 2001.
The noni plant was used in traditional healing throughout Polynesia and is being promoted worldwide for all kinds of health problems and diseases.
"It's a $2 billion product with incredible commercialization," Issell said."We need to know if it helps more than harms people."
His study is the first to look at the effects of noni on people and see if it does what ads claim.
"We've seen pretty much improvements across the board when we look statistically, but these are early days," Issell said."It's not telling us it's going to help more than harm people, but what dose we will test in the future."
The team, including Faith Inoshita, clinical research nurse, is trying to complete the first phase of the study to find the right dose that will be effective for people, Issell said.
...
"We have been seeing increasing improvement in quality of life measures," Issell said."It's very interesting.
...
"We're measuring different markers," Issell said."Once we have something we can feel confident about, we will use it to standardize noni because there are hundreds of different products now from juice, with additional things to mask the dose."
Noni Maui is providing fruit grown on the Big Island for the study, which requires a consistent supply, Issell said: "We have quite a lot of capsules and will continue up to 40 (per day) if we need to."
...
The first phase of the study began with National Institutes of Health funding and it is continuing with support from the Hawaii Community Foundation, Issell said.
He said the issue with cancer drugs is to find the maximum tolerated dose that's most likely to have an anti-cancer effect.
"Here, we haven't found the maximum-tolerated dose," he said.
...
Issell gets inquiries about noni from all over the world, Gotay pointed out: "That's partly why we are so cautious.
Other People with the name "Issell":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304